1. Home
  2. COEP vs GRNQ Comparison

COEP vs GRNQ Comparison

Compare COEP & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • GRNQ
  • Stock Information
  • Founded
  • COEP 2017
  • GRNQ 2013
  • Country
  • COEP United States
  • GRNQ Malaysia
  • Employees
  • COEP N/A
  • GRNQ N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • GRNQ EDP Services
  • Sector
  • COEP Health Care
  • GRNQ Technology
  • Exchange
  • COEP Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • COEP 8.1M
  • GRNQ 7.2M
  • IPO Year
  • COEP N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • COEP $0.21
  • GRNQ $0.97
  • Analyst Decision
  • COEP
  • GRNQ
  • Analyst Count
  • COEP 0
  • GRNQ 0
  • Target Price
  • COEP N/A
  • GRNQ N/A
  • AVG Volume (30 Days)
  • COEP 282.8K
  • GRNQ 39.1K
  • Earning Date
  • COEP 11-13-2024
  • GRNQ 11-13-2024
  • Dividend Yield
  • COEP N/A
  • GRNQ N/A
  • EPS Growth
  • COEP N/A
  • GRNQ N/A
  • EPS
  • COEP N/A
  • GRNQ N/A
  • Revenue
  • COEP N/A
  • GRNQ $2,727,344.00
  • Revenue This Year
  • COEP N/A
  • GRNQ N/A
  • Revenue Next Year
  • COEP N/A
  • GRNQ N/A
  • P/E Ratio
  • COEP N/A
  • GRNQ N/A
  • Revenue Growth
  • COEP N/A
  • GRNQ N/A
  • 52 Week Low
  • COEP $0.15
  • GRNQ $0.77
  • 52 Week High
  • COEP $1.33
  • GRNQ $1.88
  • Technical
  • Relative Strength Index (RSI)
  • COEP 50.31
  • GRNQ 53.45
  • Support Level
  • COEP $0.19
  • GRNQ $0.91
  • Resistance Level
  • COEP $0.22
  • GRNQ $1.25
  • Average True Range (ATR)
  • COEP 0.02
  • GRNQ 0.11
  • MACD
  • COEP -0.00
  • GRNQ 0.01
  • Stochastic Oscillator
  • COEP 46.15
  • GRNQ 37.64

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management, cross-border listing advisory services, and transaction services. It also operates a venture capital business. Its segments include Service business engaged in the provision of corporate advisory and business solution services; and Real estate business engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia.

Share on Social Networks: